The WasteWatcher: The Staff Blog of Citizens Against Government Waste

Pharmaceuticals

New HHS Transparency Regulation Mandates Inaccurate Information

The Pharmaceutical Research Manufacturers Association (PhRMA), the trade association that represents the nation’s leading biopharmaceutical research companies, announced a new proposal on Monday regarding direct-to-consumer (DTC) television advertising.  This voluntary agreement by PhRMA members would help patients access more useful information about the cost of their medicines.

Importation Will Not Lower Drug Costs

Citizens Against Government Waste (CAGW) was disappointed to see that the Trump Administration announced on Thursday, July 19, that the Food and Drug Administration (FDA) is exploring ways to import lower cost drugs from foreign countries.  Since most countries utilize price controls to determine a drug’s cost, the U.S.

President Trump’s Blueprint to Lower Drug Costs: A Lot to Unpack

On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.

President Trump's Drug Costs Proposals Coming Soon

The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.

Stealing Patents Won’t Bring Down Drug Costs

On February 15, 2018, 18 Democratic members of Congress sent a letter to Health and Human Services (HHS) Secretary Alex Azar, asking him to use his authority under 28 U.S.C.

Drug Prices - The Council of Economic Advisers and Trump Administration Weigh In

Last Friday, on February 9, 2018, the White House Council of Economic Advisers released a 30-page report on, “Reforming Biopharmaceutical Pricing at Home and Abroad.”  There is enough in the report to please or give heartburn to all the players in the pharmaceutical distribution chain but, there are many significant ideas that policy makers should and will consider.  President Trump’s administration has already done so for its 2019 budget proposal, which will be discussed briefly in this blog.

Taxpayers and Patients Win First Round on 340B Drug Discount Rule

Citizens Against Government Waste (CAGW) discussed in its November 7, 2017 WasteWatcher blog, a Centers for Medicare and Medicaid Services (CMS) final rule for Medicare Part B that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program.

Rogue "Drug" Companies Face Congress

On Thursday, February 4, the House Committee on Oversight and Government Reform held a hearing entitled, “Developments in the Prescription Drug Market.”

Judge Tells Federal Agency to Obey the Law for Drug Discount Program

On October 14, the United States District Court for the District of Columbia struck down the Health Resources and Services Administration’s (HRSA) interpretive rule that ordered pharmaceutical manufacturers to provide substantial drug discounts under the 340B program for orphan drugs that were used off-label.  The agency had first written a proposed rule in 2011 that was in clear violation of the Affordable Care Act (ACA), better known as Obamacare, and had stubbornly fought to implement it.

More of the Same

Presidential candidate and former-Secretary of State Hillary Clinton proposed several worn-out initiatives this Tuesday that would supposedly lower drug prices but, if implemented, would seriously damage research and development in the United States while harming patients well into the future.  Many promising drugs would either never be discovered or be severely delayed in reaching the market.

Pages

Sign Up for Email Updates!Click Here!

View Archives

Posts by Author

Posts by Tag

Big Government (152) Obamacare (76) Waste (74) Congress (72) Healthcare (70) Budget (69) Uncategorized (56) Telecommunications (50) Internet (48) Technology (46) Debt (43) Deficit (43)